# Jorge Conde

> Jorge Conde is a General Partner on the Bio + Health team at Andreessen Horowitz (a16z), where he invests at the intersection of biology, computer science, and engineering. Born in Miami to Cuban and Peruvian parents, Conde co-founded Knome — the first company to offer whole-genome sequencing directly to consumers — alongside Harvard geneticist George Church, then spent years as CSO, CFO, and CPO at Syros Pharmaceuticals before joining a16z in 2017. An MIT Technology Review Innovator Under 35 and Henry Crown Fellow at the Aspen Institute, he is one of the most prominent voices arguing that the 21st century belongs to biology the way the 20th belonged to physics.

- **Role:** General Partner at Andreessen Horowitz (a16z)
- **Organizations:** Andreessen Horowitz (a16z), Asimov (board), Cartography Biosciences (board), Dyno Therapeutics (board), Earli (board), Komodo Health (board), Octant Bio (board), Third Arc Bio (board), Aspen Institute (Henry Crown Fellow)
- **From:** Miami, United States
- **Nationality:** American
- **Education:** MBA, Harvard Business School, MS, Biomedical Enterprise, Harvard-MIT Division of Health Sciences and Technology, BA, Biology, Johns Hopkins University
- **Known for:** MIT Technology Review Innovator Under 35 (2009), Henry Crown Fellow, Aspen Institute (2015), Co-founded Knome — the world's first consumer whole-genome sequencing company with George Church

## Career timeline

- **~1990s** — Graduated Johns Hopkins University with BA in Biology
- **~early 2000s** — Worked in marketing and operations at MedImmune
- **~mid 2000s** — Biotechnology investment banker at Morgan Stanley
- **~2000s** — Earned MBA from Harvard Business School and MS from Harvard-MIT HST
- **2007** — Co-founded Knome with George Church — first consumer whole-genome sequencing company; served as CEO
- **2009** — Named MIT Technology Review Innovator Under 35
- **2015** — Knome acquired by Tute Genomics; named Henry Crown Fellow at Aspen Institute
- **~2015-2017** — Served as Chief Strategy Officer, CFO, and Chief Product Officer at Syros Pharmaceuticals (NASDAQ: SYRS)
- **2017** — Joined Andreessen Horowitz as General Partner on the Bio + Health team
- **2021** — a16z raises $750M Bio Fund III; Conde leads investments in Dyno, Komodo Health, Octant Bio
- **2024** — Published 'Big Ideas 2024: Programming Medicine's Final Frontier'
- **2026** — Led investments in Phylo ($13.5M seed) and Third Arc Bio ($52M Series A extension); joined both boards

## Achievements

- MIT Technology Review Innovator Under 35 (2009)
- Henry Crown Fellow, Aspen Institute (2015)
- Co-founded Knome — the world's first consumer whole-genome sequencing company with George Church
- General Partner overseeing a16z's $2.2B Bio + Health fund
- Backed three companies acquired by major pharma: IDRx (GSK), EQRx (Revolution Medicines), Tmunity (Gilead/Kite)
- Authored 80+ articles and podcast episodes on the future of biology and medicine
- Named a top investor in biotech, crypto, and web3 by Signal/NFX

## Latest updates

- **2026-02** — Led a16z's investment in Phylo's $13.5M seed round; joined board — thesis: biology needs an integrated environment like software has IDEs
- **2026-02** — Joined Third Arc Bio's board as a16z participated in $52M Series A extension for precision immunology platform
- **2024-12** — Featured in a16z's 'Big Ideas 2024' on programming medicine's final frontier via YouTube

## Links

- Website: https://a16z.com/author/jorge-conde/
- LinkedIn: http://www.linkedin.com/in/jorge-conde-4099225
- Twitter/X: https://twitter.com/JorgeCondeBio
- YouTube: https://www.youtube.com/watch?v=8wnNIGsIOvY

---

Profile page: https://yespress.io/jorge-conde
Published by YesPress — https://yespress.io
Last updated: 2026-05-09